Goldilocks Therapeutics Inc CEO Arthur Klausner sat down with Proactive's Christine Corrado at BIO CEO in New York.
The New York-based early-stage bio-pharmaceutical company's kidney-targeting "mesoscale nanoparticle" technology was developed at Memorial Sloan Kettering Cancer Center for the prevention and treatment of acute kidney injury and polycystic kidney disease.